Merrimack Pharmaceuticals And Sanofi-aventis Initiate Enrollment In A Phase 2 Combina
 

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients. MM-121, Merrimack's lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3...

More...